CRISPR/Cas Applications in Myotonic Dystrophy: Expanding Opportunities

CRISPR/Cas technology holds promise for the development of therapies to treat inherited diseases. Myotonic dystrophy type 1 (DM1) is a severe neuromuscular disorder with a variable multisystemic character for which no cure is yet available. Here, we review CRISPR/Cas-mediated approaches that target...

Descripción completa

Detalles Bibliográficos
Autores principales: Raaijmakers, Renée H.L., Ripken, Lise, Ausems, C. Rosanne M., Wansink, Derick G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696057/
https://www.ncbi.nlm.nih.gov/pubmed/31357652
http://dx.doi.org/10.3390/ijms20153689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696057/
https://www.ncbi.nlm.nih.gov/pubmed/31357652
http://dx.doi.org/10.3390/ijms20153689

Ejemplares similares